| Stereochemistry | ACHIRAL |
| Molecular Formula | C15H17N3O |
| Molecular Weight | 255.315 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C2N3CCN(C)C4=NCCC(C2=C1)=C34
InChI
InChIKey=GVXBHSBKKJRBMS-UHFFFAOYSA-N
InChI=1S/C15H17N3O/c1-17-7-8-18-13-4-3-10(19-2)9-12(13)11-5-6-16-15(17)14(11)18/h3-4,9H,5-8H2,1-2H3
| Molecular Formula | C15H17N3O |
| Molecular Weight | 255.315 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Metralindole (Inkazan) is a reversible inhibitor of monoamine oxidase A (RIMA) which was used in Russia as an antidepressant. Inkasan (3-methyl-8-methoxy-3H, 1,2,5,6- tetrahydropyrazine /1.2.3-ab/-beta-carboline hydrochloride) has pharmacological properties characteristic of antidepressants. The clinical antidepressant effect of inkasan is combined with stimulating action. The drug is primarily indicated for patients in whom adynamic (anergic) disturbances are predominant in the clinical picture of depression.
CNS Activity
Approval Year
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
Drug as victim
Tox targets
PubMed
Patents
Sample Use Guides
Cats: Electroencephalographic investigations conducted by L. F. Roshchina showed that in cats
inkazan in doses of 10-40 mg/kg (intravenously) caused increased cortical and subcortical
activity and intensified the reaction of cortex to photo- and photon stimulation. The electrophysiological
response of inkazan persists for 3-4 h. In doses of 5-50 mg/kg administered
intraperitoneally, the preparation slows conditioned reflexes of avoidance in rats.
Route of Administration:
Other
